| Date | Time | Source | Headline | Symbol | Company |
| 05/09/2016 | 4:02PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2016 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/27/2016 | 4:05PM | Business Wire | Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Qu... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/26/2016 | 8:00AM | Business Wire | Enanta Pharmaceuticals to Present at the Deutsche Bank 41st Annual Healthcare Conference Presentation to be Webcast on May 4,... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/25/2016 | 9:10AM | Business Wire | Enanta Announces U.S. FDA has Approved AbbVie’s Supplemental New Drug Application for Use of VIEKIRA PAK® without Ribaviri... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/25/2016 | 9:00AM | PR Newswire (US) | AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and riton... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/16/2016 | 1:10AM | Business Wire | Enanta Announces New Data from AbbVie’s SURVEYOR-1 & SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates aft... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/16/2016 | 1:00AM | PR Newswire (US) | AbbVie Presents New Phase 2 Data for Investigational, Once-Daily, Ribavirin-Free, Pan-Genotypic Regimen of ABT-493 and ABT-53... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/15/2016 | 1:15AM | Business Wire | Enanta Announces that AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 & ABT-530 Shows High SVR Rates in Genotype... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/15/2016 | 1:00AM | PR Newswire (US) | AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patient... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/15/2016 | 1:00AM | PR Newswire (US) | AbbVie Announces Real-World Data with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/14/2016 | 8:22PM | Business Wire | Enanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless of the Presence of Resistance-Associated Va... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/14/2016 | 1:11AM | Business Wire | Enanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless of the Presence of Resistance-Associated Va... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 04/14/2016 | 1:00AM | PR Newswire (US) | AbbVie Announces High SVR Rates with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) R... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/30/2016 | 7:07AM | Business Wire | Enanta Pharmaceuticals Announces HCV Data Presentations at The International Liver Congress™ 2016 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/30/2016 | 7:00AM | PR Newswire (US) | AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Invest... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/10/2016 | 8:00AM | Business Wire | Enanta Pharmaceuticals to Present at the Barclays Global Healthcare Conference | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 03/09/2016 | 6:47PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/29/2016 | 5:25PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/26/2016 | 9:52AM | Business Wire | Enanta Pharmaceuticals Announces CHMP Positive Opinion for AbbVie’s VIEKIRAX® + EXVIERA® Without Ribavirin for the Treatm... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/26/2016 | 9:52AM | PR Newswire (US) | AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir table... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/26/2016 | 9:33AM | PR Newswire (US) | AbbVie Receives CHMP Positive Opinion for VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir table... | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/17/2016 | 11:24AM | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/17/2016 | 10:08AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/16/2016 | 4:28PM | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/12/2016 | 4:11PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/12/2016 | 4:10PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/12/2016 | 9:09AM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/08/2016 | 4:14PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/08/2016 | 4:02PM | Business Wire | Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015 | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |
| 02/03/2016 | 12:52PM | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ENTA | Enanta Pharmaceuticals Inc |